w_pro1 cancer vaccine
Generic: W_pro1 Cancer Vaccine
w_pro1 cancer vaccine: 1 clinical trial tracked.
w_pro1 cancer vaccine evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about w_pro1 cancer vaccine, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (1)
First-in-human, Dose Titration and Expansion Trial to Evaluate Safety, Immunogenicity and Preliminary Efficacy of W_pro1 (BNT112) Monotherapy and in Combination With Cemiplimab in Patients With Prostate Cancer
Primary endpoint: Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)
InterventionalRandomizedopen75 targetStarted 2019-12Completion 2024-0122 sites · Germany, Hungary, United Kingdom, United StatesBioNTech SE